ASX:CSLBiotechs
CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England
CSL (ASX:CSL) saw its stock price rise by 3% over the last month, amid important developments and a fluctuating market environment. CSL Vifor's notable progress with the National Institute for Health and Care Excellence recommending sparsentan for primary IgA nephropathy treatment may have provided positive momentum. This significant medical endorsement, alongside CSL's continued engagement with shareholders through meetings, could have added weight to its share performance. Meanwhile,...